Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSD | P07339 | 4/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484068 | 0.88 | PSENEN (0.47) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL30539290 | 0.87 | PSENEN (0.55) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL8835847 | 0.85 | PSENEN (0.71) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL1486221 | 0.85 | PSENEN (0.62) | PSENENCTSKCTSSCTSDCA2 | |
| SCHEMBL1486223 | 0.85 | PSENEN (0.62) | PSENENCTSKCTSSCTSDCA2 | |
| SCHEMBL245495 | 0.85 | PSENEN (0.62) | PSENENCTSKCTSSCTSDCA2 | |
| SCHEMBL22648606 | 0.84 | PSENEN (0.63) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL22636250 | 0.84 | PSENEN (0.63) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL22636252 | 0.84 | PSENEN (0.63) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL23743087 | 0.83 | CTSS (0.56) | PSENENCTSKCTSSCTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | AGENSYS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | AGENSYS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | DDOST, VIP, THPO | PSENEN 3639/4885CTSK 2093/4885CTSS 3180/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | PSENEN 4087/4885CTSK 2772/4885CTSS 2592/4885 |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | VIP, DDOST, DNPEP | PSENEN 3625/4885CTSK 3256/4885CTSS 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.